Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Bryan K. Kee"'
Publikováno v:
International Journal of Surgical Oncology, Vol 2012 (2012)
Patients with rectal cancers, due to the unique location of the tumor, have a recurrence pattern distinct from colon cancers. Advances in adjuvant therapy over the last three decades have played an important role in improving patient outcomes. This a
Externí odkaz:
https://doaj.org/article/5c38850151304e5f8f6b8a1bfea1e094
Autor:
Ignacio I Wistuba, Andrew Futreal, Xuemei Wang, Arvind Dasari, Cathy Eng, Scott Kopetz, Edwin R Parra, Cara L Haymaker, Eduardo Vilar, Robert A Wolff, Kanwal Raghav, Michael J Overman, Younghee Lee, Benny Johnson, Luisa Maren Solis Soto, Jane V Thomas, Van K Morris, Bryan K Kee, Christine M Parseghian, Daniele Lorenzini, Caddie Laberiano-Fernandez, Anuj Verma, Wenhua Lang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background Monotherapy with immune checkpoint blockade is ineffective for patients (pts) with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This study investigates whether the combination of trametinib (T) with durvalumab (D) can a
Externí odkaz:
https://doaj.org/article/df046ec2d0ff48c99275fc303b6ac56b
Autor:
Van K. Morris, Michael J. Overman, Michael Lam, Christine M. Parseghian, Benny Johnson, Arvind Dasari, Kanwal Raghav, Bryan K. Kee, Ryan Huey, Robert A. Wolff, John Paul Shen, June Li, Isabel Zorrilla, Ching-Wei D. Tzeng, Hop S. Tran Cao, Yun Shin Chun, Timothy E. Newhook, Nicolas Vauthey, Dzifa Duose, Raja Luthra, Cara Haymaker, Scott Kopetz
Publikováno v:
Cancer Res Commun
Identification of circulating tumor DNA (ctDNA) following curative intent therapies is a surrogate for microscopic residual disease for patients with metastatic colorectal cancer (mCRC). Preclinically, in micrometastatic microsatellite stable (MSS) c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd32a40e422d9ad04c0373b193c33e1a
https://doi.org/10.1158/2767-9764.crc-22-0194
https://doi.org/10.1158/2767-9764.crc-22-0194
Autor:
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep. Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Publikováno v:
Cancer Immunology Research.
IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d46977681ac8a5cbd10f04dd9e8a6e33
https://doi.org/10.1158/2326-6066.cir-22-0444
https://doi.org/10.1158/2326-6066.cir-22-0444
Autor:
Scott Kopetz, Cara Haymaker, Raja Luthra, Dzifa Duose, Nicolas Vauthey, Timothy E. Newhook, Yun Shin Chun, Hop S. Tran Cao, Ching-Wei D. Tzeng, Isabel Zorrilla, June Li, John Paul Shen, Robert A. Wolff, Ryan Huey, Bryan K. Kee, Kanwal Raghav, Arvind Dasari, Benny Johnson, Christine M. Parseghian, Michael Lam, Michael J. Overman, Van K. Morris
Supplemental Figure S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23047c1c7af615af907aa9b1ff30b2be
https://doi.org/10.1158/2767-9764.22545027
https://doi.org/10.1158/2767-9764.22545027
Autor:
Scott Kopetz, Cara Haymaker, Raja Luthra, Dzifa Duose, Nicolas Vauthey, Timothy E. Newhook, Yun Shin Chun, Hop S. Tran Cao, Ching-Wei D. Tzeng, Isabel Zorrilla, June Li, John Paul Shen, Robert A. Wolff, Ryan Huey, Bryan K. Kee, Kanwal Raghav, Arvind Dasari, Benny Johnson, Christine M. Parseghian, Michael Lam, Michael J. Overman, Van K. Morris
Supplemental Table S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45bfafcb5bba1d4f82234d718a8d7a1f
https://doi.org/10.1158/2767-9764.22545018
https://doi.org/10.1158/2767-9764.22545018
Autor:
Scott Kopetz, Cara Haymaker, Raja Luthra, Dzifa Duose, Nicolas Vauthey, Timothy E. Newhook, Yun Shin Chun, Hop S. Tran Cao, Ching-Wei D. Tzeng, Isabel Zorrilla, June Li, John Paul Shen, Robert A. Wolff, Ryan Huey, Bryan K. Kee, Kanwal Raghav, Arvind Dasari, Benny Johnson, Christine M. Parseghian, Michael Lam, Michael J. Overman, Van K. Morris
Identification of circulating tumor DNA (ctDNA) following curative intent therapies is a surrogate for microscopic residual disease for patients with metastatic colorectal cancer (mCRC). Preclinically, in micrometastatic microsatellite stable (MSS) c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e4434852d47d4560f312c44fd8c7a0
https://doi.org/10.1158/2767-9764.c.6550830
https://doi.org/10.1158/2767-9764.c.6550830
Autor:
Funda Meric-Bernstam, Razelle Kurzrock, Gordon B. Mills, Geert Maertens, Erwin Sablon, Benoit Devogelaere, Sapna Patel, Bryan K. Kee, Michael J. Overman, Scott Kopetz, Rajyalakshmi Luthra, Vivek Subbiah, Ralph G. Zinner, Veronica R. Holley, Daniel D. Karp, Jennifer J. Wheler, Sarina A. Piha-Paul, Aung Naing, Apostolia M. Tsimberidou, Goran Cabrilo, Giovanni Nitti, Nishma M. Ramzanali, David Hong, Siqing Fu, Gerald S. Falchook, Bart Claes, Helen J. Huang, Filip Janku
Cell-free (cf) DNA from plasma offers an easily obtainable material for BRAF mutation analysis for diagnostics and response monitoring. In this study, plasma-derived cfDNA samples from patients with progressing advanced cancers or malignant histiocyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61ef94582c1c6f3d6a2f4d621403ca07
https://doi.org/10.1158/1535-7163.c.6537582.v1
https://doi.org/10.1158/1535-7163.c.6537582.v1
Autor:
Funda Meric-Bernstam, Razelle Kurzrock, Gordon B. Mills, Geert Maertens, Erwin Sablon, Benoit Devogelaere, Sapna Patel, Bryan K. Kee, Michael J. Overman, Scott Kopetz, Rajyalakshmi Luthra, Vivek Subbiah, Ralph G. Zinner, Veronica R. Holley, Daniel D. Karp, Jennifer J. Wheler, Sarina A. Piha-Paul, Aung Naing, Apostolia M. Tsimberidou, Goran Cabrilo, Giovanni Nitti, Nishma M. Ramzanali, David Hong, Siqing Fu, Gerald S. Falchook, Bart Claes, Helen J. Huang, Filip Janku
Supplementary Table 1. Emergence of BRAF mutations in cfDNA; Supplementary Table 2. Patients with BRAF V600K mutations in FFPE tumor and plasma cfDNA samples; Supplementary Table 3. Experimental therapies in 34 patients with longitudinal collection o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a225a4b89a691edeccc2bf76884a81a5
https://doi.org/10.1158/1535-7163.22503987
https://doi.org/10.1158/1535-7163.22503987
Autor:
Markos Leggas, Jeffrey A. Moscow, Bryan K. Kee, Philip A. DeSimone, Brent J. Shelton, Scott Z. Fields, John R. Eckardt, Eleftheria Tsakalozou, John J. Rinehart, Susanne M. Arnold
Purpose: 7-t-Butyldimethylsilyl-10-hydroxycamptothecin (AR-67) is a novel third generation camptothecin selected for development based on the blood stability of its pharmacologically active lactone form and its high potency in preclinical models. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::431ecb4232f06be5b02beed885c5d068
https://doi.org/10.1158/1078-0432.c.6519104
https://doi.org/10.1158/1078-0432.c.6519104